Muzaffer Ugraklı - Publications

Integrated Inflammatory and Nutritional Biomarkers in Metastatic Renal Cell Carcinoma Treated with Second- or Later-Line Nivolumab: A Retrospective Cohort Study.

Journal: Medicina (Kaunas, Lithuania)

Published: June 04, 2026

Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors: A Multicenter Study by the Turkish Oncology Group (TOG).

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: January 06, 2026

Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors: A Multicenter Study by the Turkish Oncology Group (TOG).

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: January 06, 2026

The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study.

Journal: Medicina (Kaunas, Lithuania)

Published: November 24, 2025

Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 14, 2025

Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG).

Journal: Journal of chemotherapy (Florence, Italy)

Published: September 11, 2025

Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study.

Journal: Current medical research and opinion

Published: June 10, 2024

Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.

Journal: The oncologist

Published: August 04, 2023

The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study.

Journal: Journal of cancer research and clinical oncology

Published: April 07, 2023

Could the concomitant use of beta blockers with bevacizumab improve survival in metastatic colon cancer?

Journal: European journal of clinical pharmacology

Published: January 11, 2023

Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group.

Journal: Medicine

Published: December 23, 2022

Major and minor salivary gland cancers: A multicenter retrospective study.

Journal: Head & neck

Published: November 24, 2022